SCHEMBL5869160

SCHEMBL5869160

Cc1cn(-c2nc(C(=O)CC(=O)Nc3cc(-c4ccccc4F)ccc3NC(=O)OC(C)(C)C)cs2)cn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LDHA P00338 2/20 0.37
TLR9 Q9NR96 1/20 0.36
TLR8 Q9NR97 1/20 0.36
TLR7 Q9NYK1 1/20 0.36
GPR142 Q7Z601 4/20 0.35
TRPV1 Q8NER1 1/20 0.34
HDAC3 O15379 2/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
NCOR2 Q9Y618 1/20 0.33
KCNH2 Q12809 1/20 0.33
CYP17A1 P05093 1/20 0.33
PSEN1 P49768 3/20 0.32
PSEN2 P49810 3/20 0.32
APH1B Q8WW43 3/20 0.32
NCSTN Q92542 3/20 0.32
APH1A Q96BI3 3/20 0.32
PSENEN Q9NZ42 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5869009 0.89 TLR9 (0.39) LDHATLR9TLR8TLR7GPR142
SCHEMBL5868815 0.88 CHEK1 (0.40) LDHATLR9TLR8TLR7TRPV1
SCHEMBL7464517 0.81 ACHE (0.36) TRPV1HDAC3HDAC1HDAC2HDAC10
SCHEMBL5868977 0.77 CYP17A1 (0.39) TLR9TLR8TLR7HDAC1HDAC2
SCHEMBL5868951 0.74 CYP17A1 (0.37) TRPV1CYP17A1MAPT
SCHEMBL5563091 0.74 CYP17A1 (0.41) CYP17A1PSEN1PSEN2APH1BNCSTN
SCHEMBL5868832 0.74 F2 (0.36) TRPV1CYP17A1MAPTTGFBR1
SCHEMBL5558572 0.74 SCN5A (0.41) HDAC3HDAC1HDAC2HDAC10HDAC6
SCHEMBL5868897 0.73 CYP17A1 (0.40) HDAC1CYP17A1MAPT
SCHEMBL5869050 0.73 ALDH1A1 (0.36) KCNH2PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151098-B2 Glutamate receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2006-12-19 US disclosed
US-20060148791-A1 Glutamate receptor antagonists ADAM GEO 2006-07-06 US disclosed
US-7018998-B2 Glutamate receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2006-03-28 US disclosed
US-6960578-B2 Glutamate receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2005-11-01 US disclosed
US-20050234048-A1 Glutamate receptor antagonists ADAM GEO 2005-10-20 US disclosed
EP-1224175-B1 BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2004-03-17 EP disclosed
US-20030092677-A1 Glutamate receptor antagonists ADAM GEO (DE) 2003-05-15 US disclosed
US-6509328-B1 Metabotropic glutamate receptor antagonists and accordingly are useful for the treatment of a range of neurological disorders, including psychosis, schizophrenia, Alzheimer's and others HOFFMANN-LA ROCHE INC. 2003-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092677-A1 Glutamate receptor antagonists GRM1, GRM3, GRM2 LDHA 4026/4885TLR9 1431/4885TLR8 2083/4885
US-20050234048-A1 Glutamate receptor antagonists GRM3, GRM1, GRM2 LDHA 4166/4885TLR9 1302/4885TLR8 1698/4885
US-20060148791-A1 Glutamate receptor antagonists GRM3, GRM1, GRM2 LDHA 4166/4885TLR9 1302/4885TLR8 1698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.